Application of gas chromatography-mass spectrometry for analysis of isoprostanes: Their role in cardiovascular disease

Clinical Chemistry and Laboratory Medicine

Volumn 41, Issue 12, 2003, Pages 1552-1561

  Schwedhelm, Edzard ^a   Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

8 iso PGF2 *iPF2 III; Biomarker; Cardiovascular disease; Gas chromatography tandem mass spectrometry; Isoprostanes; Lipid peroxidation; Oxidative stress; Urinary isoprostane metabolites

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ALPHA TOCOPHEROL; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIOXIDANT; ARACHIDONIC ACID DERIVATIVE; ARGININE; ASCORBIC ACID; BIOCHEMICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPROSTANE DERIVATIVE; LIPID; NONSTEROID ANTIINFLAMMATORY AGENT;

ANALYTIC METHOD; BODY FLUID; CANCER; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CHEMICAL ANALYSIS; DRUG BLOOD LEVEL; ENZYME IMMUNOASSAY; GAS CHROMATOGRAPHY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOLOGICAL PROCEDURES; LIPID PEROXIDATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOLECULAR STABILITY; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RELIABILITY; REVIEW; TANDEM MASS SPECTROMETRY; WESTERN HEMISPHERE;

BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; ISOPROSTANES; LIPID PEROXIDATION; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 0347355284     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2003.238     Document Type: Review

References (122)

1. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol 2003; 91:7A 11A.
2. Rice-Evans C, Miller NJ. Total antioxidant status in plasma and body fluids. Methods Enzymol 1994; 234:279 93.
3. Prior RL, Cao G. In vivo total antioxidant capacity: comparison of different analytical methods. Free Radic Biol Med 1999; 27:1173 81.
4. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 1989; 6:67 75.
5. Meagher EA, FitzGerald GA. Indices of lipid peroxidation in vivo: strengths and limitations. Free Radic Biol Med 2000; 28:1745 50.
6. Halliwell B. Lipid peroxidation, antioxidants and cardiovascular disease: how should we move forward? Cardiovasc Res 2000; 47:410 8.
7. Morrow JD, Roberts II LJ. The isoprostanes: unique bioactive products of lipid peroxidation. Prog Lipid Res 1997; 36:1 21.
8. Morrow JD, Minto TA, Mukundan CR, Campbell MD, Zackert WE, Daniel V, et al. Free radical-induced generation of Isoprostanes in vivo: evidence for the formation of D-ring and E-ring isoprostanes in vivo. J Biol Chem 1994; 269: 4317 26.
9. Morrow JD, Awad JA, Wu A, Zackert WE, Daniel VC, Roberts II LJ. Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo. J Biol Chem 1996; 271:23185-90.
10. 2-isoprostanes: sensitive and specific non-invasive indices of lipid peroxidation in vivo. Atherosclerosis 1999; 147:1-10.
11. Morrow JD, Awad JA, Boss HJ, Blair IA, Roberts II LJ. Non-cyclooxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 1992; 89:10721-5.
12. Awad JA, Morrow JD, Takahashi K, Roberts II LJ. Identification of non-cyclooxygenase-derived prostanoid (F2-isoprostane) metabolites in human urine and plasma. J Biol Chem 1993; 268:4161-9.
13. 2-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28:505-13.
14. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci 2002; 23:360-6.
15. Thérond P, Bonnefont-Rousselot D, Davit-Spraul A, Conti M, Legrand A. Biomarkers of oxidative stress: an analytical approach. Curr Opin Clin Nutr Metab Care 2000; 3:373-84.
16. Lawson JA, Rokach J, FitzGerald GA. Isoprostanes: formation, analysis and use as indices of lipid peroxidation. J Biol Chem 1999; 274:24441-4.
17. 2-isoprostanes in biological fluids and tissues as measure of oxidant stress. Methods Enzymol 1999; 300:3-12.
18. 2α. Possible methodological, mechanistic and clinical implications. J Chromatogr B 2003; 794:237-55.
19. 2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol 1994; 233:163-74.
20. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87:9383-7.
21. 2-isoprostane regioisomers formed in vivo in the rat. Free Radical Biol Med 1997; 23:943-54.
22. 3-isoprostanes during peroxidation of eicosapentaenoic acid. Biochem Biophys Res Commun 1997; 236:467-72.
23. Roberts LJ, Montine TJ, Markesbery WR, Tapper AR, Hardy P, Chemtob S, et al. Formation of isoprostane-like compounds (neuroprostanes) in vivo from docosa-hexaenoic acid. J Biol Chem 1998; 273:13605-12.
24. Brame CJ, Salomon RG, Morrow JD, Roberts LJ. Identificaiton of extremely reactive gamma-ketoaldehydes (isolevuglandins) as a product of the isoprostane pathway and characterization of their lysyl protein adducts. J Biol Chem 1999; 274:13139-46.
25. 4-neuroprostanes) in vivo from docosahexaenoic acid. Biochemistry 2000; 39:2376-83.
26. 4-neuroprostanes) in vivo from docosahexaenoic acid. J Biol Chem 2002; 277:36076-84.
27. Yin H, Havrilla CM, Gao L, Morrow JD, Porter NA. Mechanisms for the formation of isoprostane endoperoxides from arachidonic acid: "Dioxethane" intermediates versus β-fragmentation of peroxyl radicals. J Biol Chem 2003; 278:16720-5.
28. 2-isoprostane-containing phospholipids. J Lipid Res 1993; 34:1229-35.
29. 2α. FEBS Lett 1998; 428:32-6.
30. 2α. J Biol Chem 1999; 274:1313-9.
31. 2-isoprostane diastereoisomers by mass spectrometry. J Lipid Res 2002; 43:495-509.
32. 2α, is formed in vivo. Biochim Biophys Acta 1994; 1210:244-8.
33. 2α-VI in human urine by gas chromatography/mass spectrometry. Anal Biochem 1998; 262:45-56.
34. 2α, in human urine. J Biol Chem 1998; 273:29295-301.
35. 2α in humans. J Biol Chem 1996; 271:20617-20.
36. 2) is formed in vivo. J Lipid Res 1998; 39:1589-93.
37. 2) in vivo. Biochim Biophys Acta 1999; 1436:550-6.
38. 2-isoprostanes as indicators of non-enzymatic lipid peroxidation in vivo by gas chromatography-mass spectrometry: development of a solid-phase extraction procedure. J Chromatogr B 1995; 667:199-208.
39. Nourooz-Zadeh J. Gas chromatography-mass spectrometry assay for measurement of plasma isoprostanes. Methods Enzymol 1999; 300:13-7.
40. 2-isoprostanes. Clin Chem 2001; 47:1306-8.
41. Wübert J, Reder E, Kaser A, Weber PC, Lorenz RL. Simultaneous solid phase extraction, derivatization, and gas chromatographic mass spectrometric quantification of thromboxane and prostacyclin metabolites, prostaglandins, and isoprostanes in urine. Anal Chem 1997; 69:2143-6.
42. 2-isoprostanes in umbicial cord blood of newborn by gas chromatrography-mass spectrometry. Anal Biochem 2003; 316:111-7.
43. 2-isoprostanes using gas chromatography-mass spectrometry. Anal Biochem 1999; 268:117-25.
44. 2-isoprostane analysis in plasma and urine with high-performace liquid chromatography and gas chromatography/mass spectrometry. Anal Biochem 2000; 280:73-9.
45. 2α in vivo is not affected by cyclooxygenase inhibition. Adv Prostaglandin Thromboxane Leukot Res 1995; 23:233-6.
46. 2α, a novel index of lipid peroxidation in vivo, by immunoaffinity extraction/gas chromatography-mass spectrometry. Basal levels in smokers and nonsmokers. Free Radic Biol Med 1996; 20:619-24.
47. 2α levels in health and disease. Adv Exp Med Biol 1997; 433:189-92.
48. 2α by high-performance liquid chromatography and gas chromatography-mass spectrometry. J Chromatogr B 1997; 694:271-6.
49. 2t-IsoP in rat plasma. Mol Biotechnol 2001; 18:105-18.
50. Obata T, Tomaru K, Nagakura T, Izumi Y, Kawamoto T. Smoking and oxidant stress: assay of isoprostane in human urine by gas chromatography-mass spectrometry. J Chromatogr B 2000; 746:11-5.
51. 2α type III in human urine by gas chromatography-electronic impact mass spectrometry. Comparison with enzyme immunoassay. J Chromatogr B 2001; 754:333-43.
52. Tsukamoto H, Hishinuma T, Mikkaichi T, Nakamura H, Yamazaki T, Tomioka Y, et al. Simultaneous quantification of prostaglandin, isoprostane and thromboxane in cell-cultured medium using gas chromatography-mass spectrometry. J Chromatogr B 2002; 774:205-14.
53. 2α) by gas chromatography-mass spectrometry-selected ion monitoring for medical samples. J Chromatogr B 2003; 792:131-40.
54. 2α in humans. J Mass Spectrom 1007; 32:1362-70.
55. 2α in urine of healthy humans and patients with Zellweger syndrome by gas chromatography-tandem mass spectrometry. J Chromatogr B 1998; 716:7-17.
56. 2α in human urine. J Chromatogr B 2000; 744:99-112.
57. 2-isoprostanes in human urine. Proc Natl Acad Sci USA 1999; 96:13381-6.
58. 2-isoprostanes to plaque instability in human carotid atherosclerosis. J Clin Invest 1999; 103:421-7.
59. 2α in human plasma and urine by liquid chromatography-electrospray ionisation mass spectrometry. J Chromatogr B 2000; 746:17-24.
60. 2α) by a stable isotope dilution mass spectrometric assay. Anal Biochem 1999; 269:326-31.
61. 2α) by a stable isotope dilution mass spectrometric assay. Clin Chim Acta 2001; 314:93-9.
62. 2α-III and an oxidation product of γ-linolenic acid. J Biol Chem 2000; 275:2499-504.
63. 2α-I: an index of lipid peroxidation in humans. Proc Natl Acad Sci USA 1998; 95:3449-54.
64. 2 through derivatization by O-(2,3,4,5,6-pentafluorobenzyl)hydroxyl amine. Anal Biochem 1998; 261:230-2.
65. Cracowski JL, Cracowski C, Bessard G, Pepin JL, Bessard J, Schwebel C, et al. Increased lipid peroxidation in patients with pulmonary hypertension. Am J Respir Crit Care Med 2001; 164:1038-42.
66. 2α: an index for oxidatie injury via free radical catalysed lipid peroxidation. Prostaglandins Leukot Essent Fatty Acids 1998; 58:319-25.
67. 2α excretion in man. J Pharmacol Exp Ther 1995; 275:94-100.
68. 2α: a marker for lipid peroxidation after experimental brain injury. J Neurosci Methods 1996; 68:133-6.
69. 2α in human and porcine lymphatics and lymph. Lymphology 1998; 31:186-9.
70. 2-isoprostanes as markers of in vivo lipid peroxidation - a comparison of enzyme immunoassay with gas chromatography/mass spectrometry. Anal Biochem 1999; 272:209-15.
71. 2-isoprsotanes as measures of oxidative stress in type 2 diabetes. Clin Chem 2001; 47:1974-9.
72. Keaney JF, Larson MG, Vasan RS, Wilson PW, Lipinska I, Corey D, et al. Obesity and systemic oxidative stress: clinical correlates of oxidative stress in the Framingham Study. Arterioscler Thromb Vasc Biol 2003; 23:434-9.
73. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular disease: the role of oxidant stress. Circ Res 2000; 87:840-4.
74. Dhalla NS, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular disease. J Hypertens 2000; 18:655-73.
75. Grundy SM, Pasternak R, Greenland P, Smith S, Fuster V. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 1999; 100:1481-92.
76. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340:115-26.
77. Diaz MN, Frei B, Vita JA, Keaney JF. Antioxidants and atherosclerotic heart disease. N Engl J Med 1997, 337:408-16.
78. 2-isoprostanes, are present in increased amounts in human atherosclerotic lesions. Aterioscler Thromb Vas Biol 1997; 17:3236-41.
79. 2-isoprostanes in human atherosclerotic lesions. J Clin Invest 1997; 100:2028-34.
80. Waddington EI, Croft KD, Sienuarine K, Iatham B, Puddey IB. Fatty acid oxidation products in human atherosclerotic plaque: an analysis of clinical and histopathological correlates. Atherosclerosis 2003; 167:111-20.
81. 2α in the arterial wall layers of various species: a comparison between intact and atherosclerotic areas. Prostagl Leukotr Essential Fatty Acids 2001; 64:167-71.
82. Watson AD, Leitinger N, Navab M, Faull KF, Hörkkö S, Witztum JL, et al. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 1997; 272:13597-607.
83. 2-isoprostanes in the lipid subfractions atherosclerotic plaque and in vitro oxidized low density lipoprotein. Redox Rep 2002; 7:179-84.
84. Bhakdi S, Dorweiler B, Kirchmann R, Torzewski J, Weise E, Tranum-Jensen J, et al. On the pathogenesis of atherosclerosis: enzymatic transformation of human low density lipoprotein to an atherogenic moiety. J Exp Med 1995; 182:1959-71.
85. 2α is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1997; 17:3230-5.
86. 2α in heterozygous hypercholesterolemia. Wien Klin Wochenschr 1999; 111: 113-8.
87. 2 isoprostanes in hypercholesterolemia. Circulation 1998; 98: 2822-8.
88. Cracowski JL, Devillier P, Durand T, Stanke-Labesque F, Bessard G. Vascular biology of the isoprostanes. J Vasc Res 2001; 38:93-103.
89. Cracowski JL, Baguet JP, Ormenzzano O, Bessard J, Stanke-Labesque F, Bessard G, et al. Lipid peroxidation is not increased in patients with untreated mild-to-moderate hypertension. Hypertension 2003; 41:286-8.
90. Minuz P, Patrignani P, Gaino S, Degan M, Menapace L, Tommasoli R, et al. Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. Circulation 2002; 106:2800-5.
91. Morrow JD, Roberts U. The isoprostanes: their role as an index of oxidant stress status in human pulmonary disease. Am J Respir Crit Care Med 2002; 166:S25-30.
92. Jourdan K, Mitchell J, Evans T. Release of isoprostanes by human pulmonary artery in organ culture: a cyclo-oxygenase and nitric oxide dependent pathway. Biochem Biophys Res Commun 1997; 233:668-72.
93. 2 production in isolated pulmonary artery smooth muscle cells: concomitant and differential release. FASEB J 1999; 13:1025-30.
94. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Letters 1995; 368:225-9.
95. 2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99:224-9.
96. Davi G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, et al. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 2003; 107:3199-203.
97. Cracowski JL, Baguet JP. Isoprostanes: are they more than physiopathological biomarkers of lipid peroxidation? Circulation 2003; 107:e222.
98. Block G, Dietrich M, Norkus EP, Morrow JD, Hudes M, Caan B, et al. Factors associated with oxidative stress in human populations. Am J Epidemiol 2002; 156:274-85.
99. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, et al. Platelet activation in obese women: role of inflammation and oxidant stress. J Am Med Assoc 2002; 288:2008-14.
100. 2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 59:1960-6.
101. 2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 2002; 58:190-7.
102. 2α as a useful clinical biomarker of oxidative stress in ESRD patients. Blood Purif 2002; 20:537-42.
103. 2-isoprostanes) in smokers: smoking as a cause of oxidative damage. N Engl J Med 1995; 332:1198-1203.
104. Reilly M, Delanty N, Lawson JA, FitzGerald GA. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 1996; 94:19-25.
105. Sinzinger H, Kaliman J, Oguogho A. Eicosanoid production and lymphatic responsiveness in human cigarette smokers compared with non-smokers. Lymphology 2000; 33:24-31.
106. Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, et al. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am J Respir Crit Care Med 2000; 162:1175-7.
107. Oguogho A, Lupattelli G, Palumbo B, Sinzinger H. Isoprostanes quickly normalize after quitting cigarette smoking in healthy adults. VASA 2000; 29:103-5.
108. 2α after restarting smoking. Prostaglandins Leukot Essent Fatty Acids 2001; 64:307-10.
109. Vassalle C, Botto N, Andreassi MG, Berti S, Biagini A. Evidence for enhanced 8-isoprostane plasma levels, as index of oxidative stress in vivo, in patients with coronary artery disease. Coron Artery Dis 2003; 14:213-8.
110. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102:840-5.
111. 2α, in human aortic and pulmonary valves of patients with coronary heart disease. Histol Histopathol 2002; 17:1053-9.
112. 2α generation during coronary reperfusion. A potential quantitative marker of oxidant stress in vivo. Circulation 1997; 95:24-92.
113. 2α in acute coronary angioplasty: evidence for oxidant stress during coronary reperfusion in humans. Circulation 1997; 96:3314-20.
114. Schwedhelm E, Maas R, Troost R, Boger R. Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. Clin Pharmacokinet 2003; 42:437-59.
115. Meagher EA, Barry OP, Lawson JA, Rokach J, FitzGerald GA. Effects of vitamin E on lipid peroxidation in healthy persons. J Am Med Soc 2001; 285:1178-82.
116. Ide T, Tsutsui H, Ohashi N, Hayashidani S, Suematsu N, Tsuchihashi M, et al. Greater oxidative stress in healthy young men compared with premenopausal women. Arterioscler Thromb Vasc Biol 2002; 22:438-42.
117. 2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation 2000; 102:539-45.
118. Salonen RM, Nyyssonen K, Kaikkonen J, Porkkala-Sarataho E, Voutilainen S, Rissanen TH, et al. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation 2003; 107:947-53.
119. Widlansky ME, Price DT, Gokce N, Eberhardt RT, Duffy SJ, Holbrook M, et al. Short- and long-term COX-2 inhibition reverses endothelial dysfunction in patients with hypertension. Hypertension 2003; 42:310-5.
120. Wassmann S, Hilgers S, Laufs U, Bohm M, Nickenig G. Angiotensin II type 1 receptor antagonism improves hypercholesterolemia-associated endothelial dysfunction. Arterioscler Thromb Vasc Biol 2002; 22:1208-12.
121. 2-isoprostane formation in hypercholesterolemic subjects: no further effect of vitamin E. Circulation 2002; 106:2543-9.
122. Sydow K, Schwedhelm E, Arakawa N, Bode-Böger SM, Tsikas D, Hornig B, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 2003; 57:244-52.